Teva Pharmaceutical Industries ADR (TEVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 641,000 | 311,000 | 1,285,000 | 875,000 | 633,000 |
| Depreciation Amortization | 480,000 | 1,524,000 | 1,192,000 | 615,000 | 305,000 |
| Income taxes - deferred | -217,000 | 15,000 | -397,000 | -202,000 | -51,000 |
| Accounts receivable | N/A | 343,000 | N/A | N/A | N/A |
| Other Working Capital | -797,000 | 1,219,000 | 1,100,000 | 53,000 | 189,000 |
| Other Operating Activity | 29,000 | 1,813,000 | 620,000 | 998,000 | 300,000 |
| Operating Cash Flow | $136,000 | $5,225,000 | $3,800,000 | $2,339,000 | $1,376,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 1,210,000 | 1,101,000 | 1,232,000 | -308,000 | -170,000 |
| Net Acquisitions | N/A | -36,148,000 | -35,874,000 | -2,312,000 | -2,236,000 |
| Purchase Of Investment | -6,000 | -481,000 | -316,000 | -37,000 | -29,000 |
| Other Investing Activity | 312,000 | -212,000 | 15,000 | 15,000 | 18,000 |
| Investing Cash Flow | $1,516,000 | $-35,740,000 | $-34,943,000 | $-2,642,000 | $-2,417,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -1,350,000 | 1,998,000 | 1,316,000 | 758,000 | 38,000 |
| Debt Issued | N/A | 25,581,000 | 25,580,000 | 327,000 | 326,000 |
| Debt Repayment | N/A | -999,000 | -50,000 | -43,000 | -41,000 |
| Common Stock Issued | N/A | 364,000 | 363,000 | 349,000 | 342,000 |
| Dividend Paid | -411,000 | -1,558,000 | -1,148,000 | -743,000 | -367,000 |
| Other Financing Activity | -7,000 | -169,000 | -143,000 | -102,000 | -31,000 |
| Financing Cash Flow | $-1,768,000 | $25,217,000 | $25,918,000 | $546,000 | $267,000 |
| Exchange Rate Effect | 28,000 | -660,000 | -164,000 | -205,000 | -208,000 |
| Beginning Cash Position | 988,000 | 6,946,000 | 6,946,000 | 6,946,000 | 6,946,000 |
| End Cash Position | 900,000 | 988,000 | 1,557,000 | 6,984,000 | 5,964,000 |
| Net Cash Flow | $-88,000 | $-5,958,000 | $-5,389,000 | $38,000 | $-982,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 136,000 | 5,225,000 | 3,800,000 | 2,339,000 | 1,376,000 |
| Capital Expenditure | -202,000 | -901,000 | -568,000 | -347,000 | -172,000 |
| Free Cash Flow | -66,000 | 4,324,000 | 3,232,000 | 1,992,000 | 1,204,000 |